Хайлтын үр дүнгүүд - Jeffrey Matous
- 37-н 1 - 20 үр дүнгүүдийг харуулж байна
- Дараагийн хуудас руу очих
-
1
-
2
Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia -н Ian W. Flinn, Mohamad Cherry, Michael B. Maris, Jeffrey Matous, Jesús G. Berdeja, Manish R. Patel
Хэвлэсэн 2019Artigo -
3
Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment -н Baiteng Zhao, Robert Chen, Owen A. O’Connor, Ajay K. Gopal, Radhakrishnan Ramchandren, André Goy, Jeffrey Matous, Adedigbo A. Fasanmade, Thomas Manley, Tae Hyung Han
Хэвлэсэн 2016Artigo -
4
CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies -н Tae Hyung Han, Ajay K. Gopal, Radhakrishnan Ramchandren, André Goy, Robert Chen, Jeffrey Matous, Maureen Cooper, Laurie E. Grove, Stephen C. Alley, Carmel M. Lynch, Owen A. O’Connor
Хэвлэсэн 2013Artigo -
5
Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma -н Sham Mailankody, Jeffrey Matous, Michaela Liedtke, Surbhi Sidana, Shahbaz A. Malik, Rajneesh Nath, Olalekan O. Oluwole, Erin E. Karski, Wade Lovelace, Xiangdong Zhou, Srinand Ponnathapura Nandakumar, Arun Balakumaran, Parameswaran Hari
Хэвлэсэн 2020Artigo -
6
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation -н Ajay K. Gopal, Radhakrishnan Ramchandren, Owen A. O’Connor, R.B. Berryman, Ranjana H. Advani, Robert Chen, Scott E. Smith, Maureen Cooper, Achim Rothe, Jeffrey Matous, Laurie E. Grove, Jasmine Zain
Хэвлэсэн 2012Artigo -
7
Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide -н Paul Shaughnessy, Miguel Islas‐Ohlmayer, Julie A. Murphy, Maureen Hougham, Jill MacPherson, Kurt Winkler, Matthew J. Silva, Michael Steinberg, Jeffrey Matous, Sheryl Selvey, Michael B. Maris, Peter A. McSweeney
Хэвлэсэн 2010Artigo -
8
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia -н Steven P. Treon, Andrew R. Branagan, Leukothea Ioakimidis, Jacob D. Soumerai, Christopher J. Patterson, Barry Turnbull, Parveen Wasi, Christos Emmanouilides, Stanley R. Frankel, Andrew Lister, Pierre Morel, Jeffrey Matous, Stephanie A. Gregory, Eva Kimby
Хэвлэсэн 2008Artigo -
9
S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY -н Fritz Offner, O. Decaux, Cyrille Hulin, Sébastien Anguille, Anne Sophie Michallet, Luciano J. Costa, Cyrille Touzeau, Kevin Boyd, Deeksha Vishwamitra, Yue Guo, Zhuolu Niu, Julie S. Larsen, Lingling Chen, Arnob Banerjee, Jenna D. Goldberg, Jeffrey Matous
Хэвлэсэн 2023Artigo -
10
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study -н Barbara Pro, Ranjana H. Advani, Pauline Brice, Nancy L. Bartlett, Joseph D. Rosenblatt, Tim Illidge, Jeffrey Matous, Radhakrishnan Ramchandren, Michelle A. Fanale, Joseph M. Connors, Yin Yang, Eric L. Sievers, Dana A. Kennedy, Andrei R. Shustov
Хэвлэсэн 2012Artigo -
11
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies -н Nancy L. Bartlett, Robert Chen, Michelle A. Fanale, Pauline Brice, Ajay K. Gopal, Scott E. Smith, Ranjana H. Advani, Jeffrey Matous, Radhakrishnan Ramchandren, Joseph D. Rosenblatt, Dirk Huebner, Pamela Levine, Laurie E. Grove, Andres Forero‐Torres
Хэвлэсэн 2014Artigo -
12
Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study -н Jeffrey Matous, Noa Biran, Aurore Perrot, Jesús G. Berdeja, Kathleen A. Dorritie, Janine van Elssen, Emma Searle, Cyrille Touzeau, Sébastien Anguille, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Katherine A. Thornton, Damiette Smit, Hang Quach
Хэвлэсэн 2023Artigo -
13
Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia -н Irene M. Ghobrial, Fangxin Hong, Swaminathan P. Iyer, Ashraf Badros, Meghan Rourke, Renee Leduc, Stacey Chuma, Janet Kunsman, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Edie Weller, Jeffrey Matous
Хэвлэсэн 2010Artigo -
14
Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study -н Nathan Fowler, Brad S. Kahl, Peter P. Lee, Jeffrey Matous, Amanda F. Cashen, Samuel A. Jacobs, Jeffrey Letzer, Bipinkumar Amin, Michael E. Williams, Sonali M. Smith, Alfred Saleh, Peter J. Rosen, Hongliang Shi, Sudha Parasuraman, Bruce D. Cheson
Хэвлэсэн 2011Artigo -
15
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma -н Barbara Pro, Ranjana H. Advani, Pauline Brice, Nancy L. Bartlett, Joseph D. Rosenblatt, Tim Illidge, Jeffrey Matous, Radhakrishnan Ramchandren, Michelle A. Fanale, Joseph M. Connors, Keenan Fenton, Dirk Huebner, Juan Pinelli, Dana A. Kennedy, Andrei R. Shustov
Хэвлэсэн 2017Artigo -
16
Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia -н Irene M. Ghobrial, Federico Campigotto, Timothy J. Murphy, Erica N Boswell, Ranjit Banwait, Feda Azab, Stacey Chuma, Janet Kunsman, Amanda Donovan, Farzana Masood, Diane Warren, Scott J. Rodig, Kenneth C. Anderson, Paul G. Richardson, Edie Weller, Jeffrey Matous
Хэвлэсэн 2013Artigo -
17
Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol A... -н Jorge E. Cortés, Joseph O. Moore, Richard T. Maziarz, Meir Wetzler, Michael Craig, Jeffrey Matous, Selina M. Luger, Bimalangshu R. Dey, Gary J. Schiller, Dat C. Pham, Camille N. Abboud, Muthuswamy Krishnamurthy, Archie W. Brown, Abderrahmane Laadem, Karen Seiter
Хэвлэсэн 2010Artigo -
18
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia -н Irene M. Ghobrial, Wanling Xie, Swaminathan P. Iyer, Ashraf Badros, Meghan Rourke, Renee Leduc, Stacey Chuma, Janet Kunsman, Diane Warren, Tiffany Poon, Brianna Harris, Amy Sam, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Edie Weller, Jeffrey Matous
Хэвлэсэн 2010Artigo -
19
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma -н Christine Chen, Donna Reece, David S. Siegel, Rubén Niesvizky, Ralph V. Boccia, Edward A. Stadtmauer, Rafat Abonour, Paul G. Richardson, Jeffrey Matous, Shaji Kumar, Nizar J. Bahlis, Melissa Alsina, Robert Vescio, Steven Coutré, Dennis Pietronigro, Robert Knight, Jerome B. Zeldis, S. Vincent Rajkumar
Хэвлэсэн 2009Artigo -
20
Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180 -н Steven P. Treon, Leukothea Ioakimidis, Jacob D. Soumerai, Christopher J. Patterson, Patricia Sheehy, Marybeth Nelson, Michael A. Willen, Jeffrey Matous, John Q. A. Mattern, Jakow G. Diener, George P. Keogh, Thomas J. Myers, Andy Boral, Ann Birner, Dixie Esseltine, Irene M. Ghobrial
Хэвлэсэн 2009Artigo
Хайх хэрэгслүүд:
Холбогдох сэдвүүд
Medicine
Internal medicine
Oncology
Lymphoma
Gastroenterology
Multiple myeloma
Chemotherapy
Surgery
Adverse effect
Astrobiology
Physics
Refractory (planetary science)
Rituximab
Waldenstrom macroglobulinemia
Immunology
Lenalidomide
Brentuximab vedotin
Neutropenia
Macroglobulinemia
Bortezomib
Chronic lymphocytic leukemia
Leukemia
Antibody
Bendamustine
Ibrutinib
Phases of clinical research
Regimen
CD30
Cyclophosphamide
Antibody-drug conjugate